<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02795650</url>
  </required_header>
  <id_info>
    <org_study_id>2015-004860-12</org_study_id>
    <nct_id>NCT02795650</nct_id>
  </id_info>
  <brief_title>Personalised Therapy for Metastatic ADPC Determined by Genetic Testing and Avatar Model Generation</brief_title>
  <acronym>AVATAR</acronym>
  <official_title>Personalised Therapy for Patients With Metastatic Adenocarcinoma of the Pancreas Determined by Genetic Testing and Avatar Model Generation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario de Fuenlabrada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario de Fuenlabrada</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open label, randomised phase II clinical trial for patients with
      metastatic adenocarcinoma of the pancreas. Patients randomised to the experimental arm will
      undergone tumoral biopsy before starting first line of treatment and will be administered
      personalised therapy as second or third line.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open label, randomised phase II clinical trial for patients with
      metastatic adenocarcinoma of the pancreas.

      Patients with metastatic disease will be randomised to the experimental or control arms.
      Those in the experimental arm will undergone a tumoral biopsy in order to perform exome
      sequencing, bioinformatic report, and avatar mouse models for drug testing. This information
      will allow the expertise panel to elaborate a treatment recommendation as second or third
      lines of treatment. Patients in the control arm will receive treatment as per investigator´s
      judge. The main objective of the trial is to determine whether personalised treatments
      achieve improved 1-year overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year overall survival</measure>
    <time_frame>1-year overall survival</time_frame>
    <description>Efficacy. 1-year overall survival</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Personalised treatment will be chosen for patients based on the results of tumor sequencing, bioinformatics and avatar model drug testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Investigators are allowed to chose the best option of standard treatment for patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Personalised treatment</intervention_name>
    <description>Personalised treatments include chemotherapy, targeted therapy, immunotherapy or others based on the previous test results, chosen from a database that include more than 2000 different drugs.</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment chosen per investigator´s judge</intervention_name>
    <description>Investigators are allowed to chose what they consider the best standard treatment option for their patients.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of adenocarcinoma of the pancreas.

          -  ECOG performance status 0 or 1

          -  Age ≥ 18 years old.

          -  Willingness of male and female subjects, who are not surgically sterile or
             postmenopausal, to use reliable methods of birth control (oral contraceptives,
             intrauterine devices, or barrier methods used with a spermicide) for the duration of
             the study.

          -  One or more sites of metastasis with one of the susceptible of biopsy.

          -  Measurable or evaluable disease

          -  No prior treatment with radiotherapy, surgery, chemotherapy or investigational
             treatment for the metastatic disease or no more than the three cycles of first line
             chemotherapy. Palliative radiotherapy for bone metastasis is allowed. Adjuvant or
             neoadjuvant radiotherapy or chemotherapy are allowed if they finished more that 6
             months ago and the patient has no remaining toxicities.

          -  Bone marrow function as follows, no more than 14 days prior to randomisation:

        ANC &gt; 1,500 cells/mm3 Platelets &gt; 100,000 cells/mm3 Hemoglobin ≥9 g/dl

          -  Adequate liver, renal and bone marrow functions.

               -  AST (SGOT), ALT (SGPT) ≤ 2.5 × ULN and ≤ 5 x ULN if liver metastases.

               -  Bilirubin ≤ 1,5 x ULN

               -  Albumin total ≥ 0,75 ULN

               -  Creatinine ≤ 1,5 x ULN

          -  Ability to sign informed consent

          -  Patients will be allowed to be randomised just once.

        Exclusion Criteria:

          -  Brain metastases, unless they have been previously treated and stable for 3 months at
             least (defined as no oedema, no need of steroids and stable disease in two CT scans
             separated by a minimum of 4 weeks).

          -  Locally advanced disease.

          -  Malignancies other than pancreatic cancer diagnosed within 5 years prior to
             randomization, except for adequately treated carcinoma in situ or basal or squamous
             cell skin cancer.

          -  Bacterial, viral or fungal active infection that require systemic treatment.

          -  Any contraindication for tumor biopsy.

          -  Past or present HIV or hepatitis B or C infection.

          -  Severe medical problems affecting organs or psychiatric illnesses that could interfere
             with the safety of the patient in the trial.

          -  Pregnancy or breastfeeding women.

          -  Patient will need to be informed and agree to undergo tumoral biopsy in the
             experimental arm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Hidalgo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sofía Perea, PhD</last_name>
    <phone>(+34) 91 600 65 83</phone>
    <email>ercavatar@salud.madrid.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francesca Sarno, PhD</last_name>
    <phone>(+34) 91 600 65 83</phone>
    <email>francesca.sarno@salud.madrid.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Alonso</last_name>
      <phone>(+34) 91 600 65 83</phone>
      <email>capozo@salud.madrid.org</email>
    </contact>
    <contact_backup>
      <last_name>Alonso</last_name>
    </contact_backup>
    <investigator>
      <last_name>Laura Medina, Dr, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Gutierrez, Dr, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ignacio Juez, Dr, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Guillen</last_name>
      <phone>+34913368263</phone>
      <email>carmenguillenponce@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Carmen Guillen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocio Garcia-Carbonero</last_name>
      <phone>+34913908926</phone>
    </contact>
    <investigator>
      <last_name>Rocio García-Carbonero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Feliú</last_name>
      <phone>+3497277516</phone>
    </contact>
    <investigator>
      <last_name>Jaime Feliú</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Pazo</last_name>
      <phone>+34976765500</phone>
      <phone_ext>3825</phone_ext>
    </contact>
    <investigator>
      <last_name>Roberto Pazo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 1, 2016</study_first_submitted>
  <study_first_submitted_qc>June 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2016</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic</keyword>
  <keyword>Pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

